ElinorPecsteen

Associate

Brussels + 32.2.645.14.46

Connect:

Share

Elinor Pecsteen advises international clients on a wide range of EU and national regulatory matters. Her practice focuses on life sciences, particularly the medical device, pharmaceutical, biotechnology, cosmetics, and food sectors. She also advises clients on general EU product regulation in relation to EU labeling, marketing obligations, and product safety.

Elinor assists clients on matters involving the full life cycle of products, from pre-market authorizations and conformity assessments to post-market issues, including advertising, distribution and compliance with anti-bribery/sunshine requirements, and data privacy.

Prior to being in private practice, Elinor worked for a year at the European Food Safety Authority.

Experience

  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Shiseido acquires Drunk Elephant™ for $845 millionJones Day advised Shiseido Americas Corporation in its $845 million acquisition of Drunk Elephant™.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • UPL acquires Arysta LifeScience from Platform Specialty Products Corporation for $4.2 billionJones Day advised UPL Limited ("UPL"), a leading global generic agrochemical company based in India, in connection with its subsidiary, UPL Corporation Limited’s, US$4.2 billion acquisition and related $3 billion term financing of Arysta Lifescience Inc. (“Arysta”), a global provider of crop protection solutions, including bio-solutions and seed treatment, from NYSE listed Platform Specialty Products Corporation (“Platform”).
  • International pharmaceutical company builds anti-corruption compliance programJones Day has been retained by an international pharmaceutical company to conduct anti-corruption and anti-bribery risk assessments for over 35 countries.
  • CVC Capital Partners acquires Teva's International Women's Health assets for $703 millionJones Day advised CVC Capital Partners in its $703 million acquisition of Teva Pharmaceutical Industries Ltd's International (non-US), Women's Health assets.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries, Inc. focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Pharmaceutical company seeks advice on regulatory reporting obligationsJones Day counsels a major pharmaceutical company in connection with regulatory reporting obligations in more than 40 countries regarding diverted, counterfeited, tampered with, or lost or stolen pharmaceutical product.
    • View All

    July 2020 Newsletters

    Vital Signs: Digital Health Law Update | Summer 2020

    April 2020 Newsletters

    Vital Signs: Digital Health Law Update | Spring 2020

    January 2020 Newsletters

    Vital Signs: Digital Health Law Update | Winter 2020

    June 2018 Commentaries

    The EU Pharma Incentives Review—Two Studies and a Legislative Proposal Released

    January 2018 Jones Day Publications

    Food, Dietary Supplement & Cosmetics Update | Vol. V, Issue 1

    November 2017 Jones Day Publications

    Food, Dietary Supplement & Cosmetics Update | Vol. IV, Issue 7

    September 2017 Jones Day Publications

    Food, Dietary Supplement & Cosmetics Update | Vol. IV, Issue 6

    June 2017 Jones Day Publications

    Food, Dietary Supplement & Cosmetics Update | Vol. IV, Issue 5

    June 2017 Jones Day Publications

    Guidance for European MA Holders to Prepare for Brexit, Pharmaceutical & Medical Device Update, Vol. IV, Issue III

    June 2017 Jones Day Publications

    Pharmaceutical & Medical Device Update, Vol. IV, Issue III
    View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.